HCW Biologics Inc.

For the period ended Jun 30, 2026. Filed Aug 14, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 14, 2026

HCWB$1.02-1.9%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance sheets

Condensed Balance Sheets

	December 31,	June 30,
	2025	2026
Unaudited
ASSETS
Current assets:
Cash and cash equivalents	$1,952,464	$741,324
Accounts receivable, net	32,175	18,451
Prepaid expenses	222,156	282,533
Other current assets	77,564	97,702
Total current assets	2,284,359	1,140,010
Investments	1,326,329	4,854,028
Property, plant and equipment, net	20,880,849	20,745,804
Other assets	28,476	28,476
Total assets	$24,520,013	$26,768,318
LIABILITIES AND STOCKHOLDERS’ EQUITY
Liabilities
Current liabilities:
Accounts payable	$13,143,394	$10,609,950
Accrued liabilities and other current liabilities	1,110,104	1,128,592
Short-term debt, net	6,809,215	6,561,361
Deferred revenue	—	348,270
Total current liabilities	21,062,713	18,648,173
Contingent liability - related party	692,531	692,531
Total liabilities	21,755,244	19,340,704
Commitments and contingencies (Note 12)	-
Stockholders’ equity:
Common stock:
Common, $0.0001 par value; 250,000,000 shares authorized and 546,635 shares issued at December 31, 2025; 250,000,000 shares authorized and 1,617,642 shares issued at June 30, 2026	55	161
Additional paid-in capital	111,280,560	117,690,050
Accumulated deficit	(108,515,846)	(110,262,597)
Total stockholders’ equity	2,764,769	7,427,614
Total liabilities and stockholders’ equity	$24,520,013	$26,768,318

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.